LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

R&D expenses increased 9.4% year-over-year, reflecting aggressive investment in high-priority development pipelines, including clinical trials for COVID-19 and RSV-related treatments. Hidemaru ...

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...

Dan Atkins, vice president of digital innovation and insight at Shionogi Europe, told the conference in a keynote address that the company needed to get better insights into its customers as the ...

9735.T SECOM CO., LTD.